← Leaderboards
Richard Warwick McCallum
Texas Tech University Health Scis Center
$2,744,619
Attributed
$5,489,237
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $530.3K · FY2011–24$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,489,237 · 1
By mechanism
U01$5,489,237 · 1
Top collaborators
- Irene Sarosiek17 shared
Most similar at Texas Tech University Health Scis Center
Same institution · by research overlap
- Irene Sarosiek$3,156,976
Others in their field
Top investigators on “Protocols Documentation”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Jeffrey P Krischer · University Of South Florida$562,015,656
- Lawrence Corey · Fred Hutchinson Cancer Center$498,533,651
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Judith S. Currier · University Of California Los Angeles$445,196,577
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$381,639,813
Research focus
Protocols DocumentationDiabeticStomachRegistriesAbdominal PainChronicNational Institute Of Diabetes And Digestive And Kidney DiseasesGastroparesisGastric EmptyingResponseEtiologyAffectClinical ResearchPathogenesisMeetingsSafetyDiagnosisTreatment EfficacyDouble-Blind MethodNausea And VomitingEnrollmentQuality Of LifeClinical DataDiagnostic
Grant awards (17)
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$384,000
U01 · FY2024 · DK · contact PI
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$61,800
U01 · FY2024 · DK · contact PI
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$400,000
U01 · FY2023 · DK · contact PI
Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric Participants with Symptoms of Gastroparesis$61,800
U01 · FY2023 · DK · contact PI
A multicenter, double-blind, randomized, placebo- controlled, parallel study to assess the efficacy of 5- HT4 agonist prucalopride for the treatment of diabetic and idiopathic gastroparesis$400,000
U01 · FY2022 · DK · contact PI
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$133,333
U01 · FY2021 · DK · contact PI
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$382,355
U01 · FY2020 · DK · contact PI
Administrative Supplement to Gastroparesis Consortium$147,930
U01 · FY2020 · DK · contact PI
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$386,809
U01 · FY2019 · DK · contact PI
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$374,151
U01 · FY2018 · DK · contact PI
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$378,366
U01 · FY2017 · DK · contact PI
New Concepts for Advancing Knowledge in Basic Science, Clinical, and Therapeutic Aspects of Gastroparesis$382,500
U01 · FY2016 · DK · contact PI
Continuation of the NIDDK Gastroparesis Consortium$469,368
U01 · FY2015 · DK · contact PI
Continuation of the NIDDK Gastroparesis Consortium$466,313
U01 · FY2014 · DK · contact PI
Continuation of the NIDDK Gastroparesis Consortium$386,847
U01 · FY2013 · DK · contact PI
Continuation of the NIDDK Gastroparesis Consortium$258,532
U01 · FY2012 · DK · contact PI
Continuation of the NIDDK Gastroparesis Consortium$415,133
U01 · FY2011 · DK · contact PI